匯聯金融服務(08030.HK)已提交申請要求將11月17日決定轉交予上市覆核委員會覆核
格隆匯11月21日丨匯聯金融服務(08030.HK)公佈,於2022年11月17日,公司接獲聯交所發出的函件,當中指出於2022年10月18日進行重新聆訊並考慮公司及上市科提交的所有資料後,GEM上市委員會決定公司未能根據GEM上市規則第17.26條維持足夠的營運水平及足夠價值的資產以支持其營運。因此,GEM上市委員會決定維持GEM上市委員會日期為2022年5月6日根據GEM上市規則第9.14A條取消公司上市地位的決定。
經尋求專業意見及審慎考慮後,公司已於2022年11月21日提交申請,要求將11月17日決定轉交予上市覆核委員會覆核。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.